CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
http://www.priceseries.com/trade/CTMX-CytomX-Therapeutics-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2021041920210504.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments